Items where authors include "Reisch, N."

Article

Rees, A.D., Merke, D.P., Arlt, W. et al. (12 more authors) (2024) Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasia. Endocrine Connections, 13 (8). e240150. ISSN 2049-3614

Tschaidse, L., Reisch, N. orcid.org/0000-0002-7469-6069, Arlt, W. orcid.org/0000-0001-5106-9719 et al. (15 more authors) (2023) Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia. European Journal of Endocrinology, 188 (1). lvac006. pp. 109-117. ISSN 0804-4643

Merke, D.P., Mallappa, A., Arlt, W. et al. (14 more authors) (2021) Modified-release hydrocortisone in congenital adrenal hyperplasia. The Journal of Clinical Endocrinology & Metabolism, 106 (5). e2063-e2077. ISSN 0021-972X

Merke, D.P., Mallappa, A., Arlt, W. et al. (14 more authors) (2020) OR25-02 A phase 3 study of a modified-release hydrocortisone in the treatment of congenital adrenal hyperplasia. Journal of the Endocrine Society, 4 (Supplement_1).

Reisch, N., Taylor, A.E., Nogueira, E.F. et al. (8 more authors) (2019) Alternative pathway androgen biosynthesis and human fetal female virilization. Proceedings of the National Academy of Sciences, 116 (44). pp. 22294-22299. ISSN 0027-8424

Jones, C.M., Mallappa, A., Reisch, N. et al. (10 more authors) (2016) Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism. jc20162855. ISSN 0021-972X

Proceedings Paper

Prete, A., Theiler-Schwetz, V., Arlt, W. et al. (13 more authors) (2024) 12670 CHAMPAIN study: initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency. In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .

Lawrence, N.R. orcid.org/0000-0002-7560-0268, Krone, N.P., Dawson, J.F. et al. (15 more authors) (2024) 6437 Analysis of 17-OH-progesterone (17OHP) and androstenedione (A4) profiles to rationalise biochemical monitoring of CAH patients. In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .

Ross, R.J.M., Merke, D.P., Mallappa, A. et al. (14 more authors) (2024) 7061 Incidence of adrenal crisis in Congenital Adrenal Hyperplasia (CAH) patients during a prospective monitored long-term study of modified-release hydrocortisone (MRHC) capsules, (Efmody). In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .

Prete, A., Theiler-Schwetz, V., Arlt, W. et al. (13 more authors) (2024) 7692 Morning cortisol levels in patients with established primary adrenal insufficiency. In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .

Prete, A., Theiler-Schwetz, V., Arlt, W. et al. (13 more authors) (2024) 9341 CHAMPAIN Study: Initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency. In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .